Stock Analysis
Maravai LifeSciences Holdings, Inc. (MRVI) Stock Analysis
Maravai LifeSciences Holdings, Inc. (MRVI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Maravai LifeSciences Holdings, Inc. (MRVI) currently has an AIQ Score of 35/100, indicating a bearish setup. Risk is the strongest factor at 46/100. Momentum is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MRVI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $6.53 |
| AIQ Score | 35/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $2.02B |
| P/E Ratio | -38.42 |
| Forward P/E | — |
| EPS | -$0.08 |
| Revenue TTM | $51.44M |
| Dividend Yield | 0.00% |
| Beta | 0.58 |
| Volume | 3.69M |
| 52-week range | $2.55-$9.42 |
| RSI 14 | 19.06 |
| 50-Day SMA | $6.83 |
| 200-Day SMA | $4.57 |
| Analyst Price Target | $6.00 |
| Next Earnings | Nov 5, 2026 |
MRVI
OverviewMRVI Stock Analysis Summary
Maravai LifeSciences Holdings, Inc. (MRVI) currently has an AIQ Score of 35/100, indicating a bearish setup. Risk resilience is the strongest factor at 46/100. Momentum is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, MRVI has AIQ Score of 35/100 with Risk resilience base of 46/100 and fading Momentum at 31/100. Wait for component alignment before adding exposure.
Healthcare · -2.97% stock move · MRVI classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MRVI Bullish or Bearish Right Now?
MRVI currently has a bearish overall setup. Risk Resilience is the strongest factor at 46/100, while Momentum is weakest at 31/100. The current evidence suggests a defensive setup.
- - No strong bullish evidence is available in the current snapshot.
- - Value is the current constraint at 34/100.
- - Momentum is weak at 31/100.
- - Analyst target implies -8.12% downside from the latest quote.
- - Technical consensus has more sell votes than buy votes (27 vs 16).
Current Consensus
MRVI's Technical Analysis Consensus is currently Sell, with 16 buy, 2 neutral, and 27 sell votes. MRVI's 14-day RSI is 19.06, which places the stock in an oversold momentum range. MRVI's beta is 0.58, indicating lower market sensitivity than the broad market.
What Changed in MRVI?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the MRVI Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MRVI Decision Framework
Public evidence layers, setup checks, and risk context for Maravai LifeSciences Holdings, Inc..
Maravai LifeSciences Holdings, Inc. (MRVI) Stock Analysis
Maravai LifeSciences Holdings, Inc. has an AIQ Score of 35/100 in a Defensive regime. Risk is strongest at 46/100. Beta is 0.58, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MRVI is in a Defensive AIQ regime with score 35/100. |
| Signal Conflict | The primary conflict is that risk leads at 46/100 while momentum lags at 31/100. |
| Factor Evidence | Momentum 31/100 · Value 34/100 · Quality 33/100 · Risk 46/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 46/100.
Momentum is 31/100 and RSI (14) is 19.1.
MRVI is in a Defensive regime at 35/100.
Risk factor is 46/100 with beta 0.58 and annual volatility 68.47%.
Current conflict: risk leads at 46/100 while momentum lags at 31/100.
MRVI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MRVI Fundamentals
MRVI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MRVI Technical Analysis
MRVI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MRVI Stock Catalysts
Track MRVI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MRVI Dividend Analysis
MRVI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MRVI Financial Data
MRVI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MRVI Risk Analysis
MRVI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MRVI Stock News
MRVI stock news, market tone, recent headlines, and catalyst context.
MRVI vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: MRVI · NTLA · NUVB · PRMB · RARE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MRVI Current stock | 35/100 | 34/100 | 31/100 | 46/100 | 1.62 | 68.47% | Current |
| NTLA Intellia Therapeutics | 32/100 | 34/100 | 27/100 | 42/100 | 0.54 | 100.40% | MRVI vs NTLA |
| NUVB Nuvation Bio | 38/100 | 34/100 | 32/100 | 43/100 | 1.06 | 85.99% | MRVI vs NUVB |
| PRMB Preimmune | 33/100 | 50/100 | 24/100 | 44/100 | -0.15 | 49.46% | MRVI vs PRMB |
| RARE Ultragenyx Pharmaceutical | 43/100 | 50/100 | 22/100 | 21/100 | -0.52 | 80.54% | MRVI vs RARE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MRVI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MRVI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MRVI Stock FAQ
What is MRVI stock price today?
Maravai LifeSciences Holdings, Inc.'s current stock price is $6.53. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MRVI bullish or bearish right now?
MRVI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MRVI's market cap?
MRVI's market cap is $2.02B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MRVI's current P/E ratio?
MRVI's current P/E ratio is -38.42 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MRVI's RSI?
MRVI's 14-day RSI is 19.06 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MRVI above its 50-day and 200-day moving averages?
MRVI is -4.43% from its 50-day SMA and 42.91% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MRVI's next earnings date?
MRVI's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MRVI pay a dividend?
MRVI's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.